SCHEMBL10312095

SCHEMBL10312095

Cc1cc(Nc2nc(/C=C/c3cccc(F)c3)nc(N3CCN(C)CC3)n2)n[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.61
AURKA O14965 11/20 0.58
AURKB Q96GD4 8/20 0.58
RET P07949 4/20 0.58
NTRK1 P04629 3/20 0.58
CSF1R P07333 3/20 0.58
FLT3 P36888 3/20 0.58
PLK4 O00444 2/20 0.58
ABL1 P00519 2/20 0.58
LCK P06239 2/20 0.58
KIT P10721 2/20 0.58
FGFR1 P11362 2/20 0.58
SRC P12931 2/20 0.58
PDGFRA P16234 2/20 0.58
TYK2 P29597 2/20 0.58
KDR P35968 2/20 0.58
PTK2 Q05397 2/20 0.58
MAP4K5 Q9Y4K4 2/20 0.58
MAP4K4 O95819 2/20 0.58
JAK2 O60674 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312175 0.97 HRH4 (0.57) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312222 0.93 HRH4 (0.50) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312086 0.91 HRH4 (0.48) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312223 0.91 HRH4 (0.61) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312135 0.91 HRH4 (0.49) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312220 0.90 NTRK1 (0.50) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312237 0.90 AURKA (0.58) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312168 0.90 AURKA (0.71) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312058 0.90 AURKA (0.71) HRH4AURKAAURKBRETNTRK1
SCHEMBL10312221 0.90 HRH4 (0.48) HRH4AURKAAURKBRETNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 HRH4 2393/4885AURKA 793/4885AURKB 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.